Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · GOLDLINE PHARMACEUTICAL LIMITE · 28 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
GOLDLINE PHARMACEUTICAL LIMITE is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY26–FY26 (all audited; no estimate years)
₹ crore · standalone
FY26
Revenue
31
EBITDA (ex other income)
—
margin %
—
Owners' profit
—
EPS, as reported (₹)
5.97
ROE % · ROCE %
— · 40.0
Debt / equity (x)
—
Cash from operations
3
Capex
(0)
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · GOLDLINE PHARMACEUTICAL LIMITE · 28 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 1 quarters
₹ crore
Q4 FY26
Revenue
17
Profit before tax
4
Net profit
—
EPS (₹)
3.43
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
Company
M.cap ₹ cr
P/E
P/B
EV/EBITDA
ROE %
ROCE %
Rev CAGR 5y %
EBITDA m. %
SUN PHARMACEUTICAL IND L
4,20,165
34.8
5.01
22.5
13.7
17.5
11.8
32.3
DIVI S LABORATORIES LTD
2,51,896
86.3
15.03
65.0
15.3
18.8
8.7
42.8
TORRENT PHARMACEUTICALS L
1,56,538
73.9
8.90
38.9
12.2
8.0
11.8
33.1
ZYDUS LIFESCIENCES LTD
1,17,055
26.1
3.96
15.1
17.3
18.0
12.4
25.2
LAURUS LABS LIMITED
1,15,722
105.7
21.31
64.4
16.4
17.2
7.2
32.0
DR. REDDY S LABORATORIES
1,09,385
33.9
2.86
14.6
10.9
13.0
12.1
15.0
CIPLA LTD
1,09,060
32.3
3.16
16.7
11.2
14.7
8.0
19.7
MANKIND PHARMA LIMITED
1,03,353
50.6
6.24
28.4
11.7
10.8
—
27.3
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
Metric
Company
Group median
Rank
Better than
P/E (TTM)
9.6
30.1
17 of 158
90%
ROCE
32.1
10.8
8 of 183
96%
Market cap
23
810
163 of 181
10%
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · GOLDLINE PHARMACEUTICAL LIMITE · 28 October 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
Date · filing
Category
Importance
Next day %
5-day %
12 Oct 2026 · Reg 74(5) compliance filing for quarter ended September 30, 2026
compliance
minimal
—
—
2 Sept 2026 · Promoter buys 60,000 shares of Goldline Pharmaceutical via open market
1 Sept 2026 · Promoter MD Amol Mujumdar buys 60,000 shares via open market
ownership changes
low
—
—
31 Aug 2026 · AGM 2026: All 8 resolutions passed with 100 percent approval
board shareholder meetings
low
—
—
29 Aug 2026 · Goldline Pharmaceutical holds 22nd AGM, first post BSE SME listing
board shareholder meetings
low
—
—
29 Aug 2026 · Promoter Swapan Khandelwal buys 78,000 shares via open market
ownership changes
medium
—
—
29 Aug 2026 · Promoter Swapan Khandelwal buys 78,000 shares (0.81%) of Goldline Pharma
ownership changes
medium
—
—
7 Aug 2026 · Goldline Pharma publishes AGM notice and e-voting details in newspapers
compliance
minimal
—
—
6 Aug 2026 · Record date set for e-voting at 22nd AGM on 29 August 2026
board shareholder meetings
low
—
—
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
Where a broker report shows
This document shows
Why
A rating (BUY / ADD / REDUCE / SELL)
A state: the latest filed quarter and the measured reactions
an event is a fact; a rating is an opinion that requires SEBI RA registration
A target price and upside
The current price and the multiples against the group
a target is a forecast; a multiple is a measurement
Estimate years marked E
More audited years; no estimates
MarketPing publishes no forecasts — your own model lives on the Models page
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
